At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More
Guidance for launches and traction in the US in the second half of FY21 and update on albuterol market share after its launch in the American market would be key things to watch out for.
Motilal Oswal feels domestic formulation business is expected to drive revenue growth, but US sales may decline 10 percent YoY.
Net Sales are expected to decrease by 0.2 percent Y-o-Y (up 0.5 percent Q-o-Q) to Rs. 3,970 crore, according to Sharekhan.
Net Sales are expected to decrease by 3 percent Y-o-Y (up 3.5 percent Q-o-Q) to Rs. 4,037.9 crore, according to KR Choksey.
Net Sales are expected to decrease by 5.4 percent Y-o-Y (up 4.8 percent Q-o-Q) to Rs. 4057.2 crore, according to Kotak.
In an interview to CNBC-TV18, Lupin Managing Director Kamal K. Sharma analysed the performance of the company in the second quarter.
Karvy Stock Broking has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Lupin Laboratories December quarter sales are expected to go up by 18.3% at Rs 1485.3 crore, Year-on-Year, (YoY) basis.